---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-224202"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2022-08-18T23:59:59+00:00"
generated_at: "2026-06-23T22:43:43.022753+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Halozyme issues $720M 1.00% convertible notes due 2028; repays term loan, buys back shares

## Summary
- Issued $720M in 1.00% Convertible Senior Notes due 2028, including $95M from over-allotment option.
- Net proceeds ~$701.4M; used to repay $250M term loan, exchange $77.6M of existing notes, and repurchase $90M of common stock.
- Initial conversion price ~$56.02 per share; capped call transactions limit dilution with cap price $75.4075.
- Increased 2022 stock repurchase authorization to $200M (from $100M) to commence after offering close.
- Capped call transactions entered with multiple counterparties to reduce dilution upon conversion.

## SEC filing metadata
- accession: 0001193125-22-224202
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2022-08-18T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/0001193125-22-224202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-224202
- JSON: https://secwatch.observer/filing/0001193125-22-224202.json
- Plain text: https://secwatch.observer/filing/0001193125-22-224202.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.